Prognostic implications of HER2 heterogeneity in gastric cancer.

about

Prognostic implications of HER2 heterogeneity in gastric cancer.

Item

http://www.wikidata.org/entity/Q55261916

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Prognostic implications of HER2 heterogeneity in gastric cancer.

@en

Prognostic implications of HER2 heterogeneity in gastric cancer.

@nl

type

Item

label

Prognostic implications of HER2 heterogeneity in gastric cancer.

@en

Prognostic implications of HER2 heterogeneity in gastric cancer.

@nl

prefLabel

Prognostic implications of HER2 heterogeneity in gastric cancer.

@en

Prognostic implications of HER2 heterogeneity in gastric cancer.

@nl

P1476

Prognostic implications of HER2 heterogeneity in gastric cancer.

@en

P2093

Hideki Kamei

http://www.w3.org/2001/XMLSchema#string

Koji Yonemoto

http://www.w3.org/2001/XMLSchema#string

Michi Morita

http://www.w3.org/2001/XMLSchema#string

Rin Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Shigenobu Motoshima

http://www.w3.org/2001/XMLSchema#string

P2860

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

P304

9262-9272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24265

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29507688

http://www.w3.org/2001/XMLSchema#string

P932

5823644

http://www.w3.org/2001/XMLSchema#string